Method

The Superpooled (SPA) Method

Triple Point's proteinase antibodies are supplied as domain-defined polyclonal pools — a pre-selected mixture of two to five independent polyclonals raised against non-overlapping epitopes of the same target. The result is a single reagent that captures the population of proenzyme, mature, cleaved, and shed forms simultaneously, without the epitope blind spots of a single-clone antibody.

Browse Superpooled kits

This page describes what the Superpooled Antibody (SPA) method is, why the pooling approach is more robust than either a single-clone monoclonal or a single-immunogen polyclonal, and how the catalogue is structured around the method. It is not a usage protocol — the Superpooled antibody usage protocol covers how to plan and interpret an experiment with a Superpooled kit.

The problem SPA solves

Consider what happens when a proteinase target is present in a real sample. In a typical whole-cell lysate, the target might exist as:

  • An ER-resident latent proenzyme (intact propeptide, full-length)
  • A Golgi-resident propeptide-cleaved but not yet fully activated intermediate
  • A fully mature active enzyme in its physiological compartment
  • An autocatalytically cleaved fragment (particularly for cathepsins)
  • An ectodomain-shed soluble form in the conditioned media
  • A cleaved cytoplasmic tail from regulated intramembrane proteolysis
  • An SDS-stable complex with a TIMP, serpin, or alpha-2-macroglobulin

All of these are the same gene product. All are biologically meaningful. A single antibody against a single epitope detects some subset and misses the rest — and the specific subset it detects depends on which epitope you happen to have chosen. Publications using such antibodies have inadvertently generated a decade of literature about specific proteinase "levels" that in fact describe specific proteinase forms, without distinguishing them.

Multi-epitope detection breaks this dependency chain. If you probe the same lysate with a panel of antibodies against propeptide, catalytic domain, and cytoplasmic tail simultaneously, you see the population as it actually is — every band at every MW, with each band's identity resolvable by which subset of antibodies detects it.

Why pooling beats running individual antibodies separately

You could, in principle, run each domain antibody in a separate lane on a separate blot. This is the "full information" experiment and remains available with the SPA kits (each kit ships the individual polyclonals separately). But the pooled protocol has three practical advantages:

Single-lane readout

One lane per sample, one exposure, one interpretation. When you are running 30 lanes for a time-course or dose-response, this collapses to 30 lanes instead of 90-150. Sample budgets are typically the binding constraint for primary research.

Additive signal at shared bands

Bands containing multiple detected epitopes get additive signal — the full-length proenzyme, detected by all antibodies, gives the strongest band. Bands containing only one epitope (a cleaved fragment) give proportionally weaker signal. The band pattern itself encodes the identity of each form.

Cross-validation built in

If two antibodies in the pool detect the same MW species, they cross-validate each other's specificity at that band. If only one detects a specific MW, that band is present but domain-defined. The interpretive framework is built into the reagent.

Why the pool is more robust than a single-clone monoclonal

A monoclonal antibody is defined by a single V-region sequence and a single epitope. Any experimental condition that affects that specific epitope — local proteolysis, PTM, buffer denaturation, epitope masking by a binding partner — abolishes signal. The monoclonal has zero redundancy.

An SPA pool has 2-5× redundancy across independently-selected epitopes on the same target. If one epitope is masked by a PTM or cleaved by autocatalytic activity, the others still detect. If one antibody has lot variation, the others buffer the pool's overall performance. The pool is robust in a way that no single-clone antibody — polyclonal or monoclonal — can be.

The trade-off is that the pool cannot claim single-epitope specificity for a cleavage-site or PTM-specific application. If you need to detect only the cleaved-caspase-3-p17 fragment and nothing else, use a specific cleavage-site monoclonal, not an SPA pool. The SPA pool is the correct reagent when you need to see the full population of forms.

Why Superpooling is uniquely suited to IHC and IF (validation in progress)

Triple Point Biologics products are currently validated for Western blot only. Immunohistochemistry (IHC) and immunofluorescence (IF) validation is on the roadmap and will be added across the catalogue as data becomes available. But the Superpooled design is not just a Western-blot optimisation — it is especially well suited to IHC and IF, for reasons that make single-clone antibodies particularly fragile in those applications. When IHC/IF validation ships, the SPA methodology will be a substantial differentiator over conventional single-clone reagents.

The mechanistic reasons the pool works better in tissue-based and cell-based imaging applications:

Fixation-induced epitope masking

Formalin fixation of tissue creates methylene bridges between primary amines on the target and surrounding proteins. This locally masks epitopes in a stochastic, epitope-specific pattern. A single-clone antibody may find its epitope completely obscured on some sections while another epitope is fully accessible on the same tissue. A multi-epitope pool retains detection on both cases — the pool has 2-5× more chances of engaging an unmasked epitope in any given tissue block.

Antigen retrieval variability

Different antigen-retrieval protocols expose different epitopes preferentially. Citrate buffer at pH 6.0 works well for some epitopes; EDTA at pH 9.0 works better for others; protease-mediated retrieval opens up cross-linked regions that heat cannot. A single-clone antibody is often locked into one retrieval condition — and if that condition doesn't work in your tissue, the antibody effectively fails. A pool typically has at least one antibody in the mixture whose epitope becomes accessible under any given retrieval protocol.

Native-fold epitope access in IF

Immunofluorescence on lightly-fixed or unfixed cells preserves native protein folding. Some epitopes are surface-exposed only in the native fold; others are buried in the native state but exposed on denaturation. A Superpooled kit designed against propeptide + catalytic + C-terminal domains will typically include at least one epitope that's accessible in both native and denatured states, so the same reagent works across preservation methods.

Signal amplification per target molecule

For fluorescence detection, signal intensity scales with the number of antibody binding events per target molecule. A single-clone antibody delivers one binding event per target. A pool delivers 2-5 binding events per target (one per epitope). This translates directly into brighter puncta, better dynamic range, and better resolution of low-abundance targets — particularly important for imaging enzymes at sub-cellular resolution.

Subcellular resolution of proteinase forms

The distinct biological forms of a proteinase (zymogen, mature, shed, cleaved) frequently occupy different subcellular compartments. A Superpooled pool can spatially resolve these: propeptide signal marks ER-resident latent forms, catalytic-domain signal marks the mature enzyme in its physiological compartment, C-terminal signal marks membrane-anchored versus shed forms. Where the individual antibodies are available in different fluorophore conjugates, an IF experiment can visualise all three forms simultaneously in different channels — a capability no single-clone antibody can offer.

Robustness across tissue types

The same brain section, tumour biopsy, or organoid may have widely varying epitope accessibility across regions — a necrotic core versus viable margin, a fibrotic region versus a healthy one. A single-clone antibody produces a spatial signal pattern that partly reflects real biology and partly reflects local epitope accessibility. A pool averages out the accessibility variation, producing a signal pattern that better reflects actual target distribution.

What this means for your future IHC/IF experiments

Because the pool composition is documented per target and the individual antibodies are supplied separately, once TPB adds IHC/IF validation data, customers who have already characterised the reagent by Western blot can transfer immediately to the tissue application without ordering a different SKU. The same three-antibody pool you used for WB is the same reagent you will use for IHC.

The retrieval conditions and dilution starting points for IHC and IF will differ from WB — that's the standard translation problem. But the reagent itself does not need to change. The Superpooled design was chosen precisely because it is application-flexible: same SKUs, same lot, same expected epitope map, adapted per protocol.

Multi-channel IF using individual pooled antibodies

Because each domain-specific antibody in an SPA kit is supplied separately, an experimenter running IF can conjugate each individually to different fluorophores (or use pre-conjugated variants) and visualise them in separate channels. For a three-antibody kit against a membrane-anchored proteinase like BACE1:

  • Channel 1 (e.g., 488): RP1BACE1 (propeptide) — marks the ER-resident latent zymogen pool
  • Channel 2 (e.g., 594): RP2BACE1 (catalytic domain) — marks total BACE1 (proenzyme + mature)
  • Channel 3 (e.g., 647): RP3BACE1 (cytoplasmic tail) — marks membrane-anchored forms

Colocalization analysis of these channels resolves the spatial distribution of each functional form. Regions with only Channel 1 mark inactive latent stores. Regions with Channels 2 + 3 but no Channel 1 mark mature membrane-anchored active enzyme. Regions with only Channel 2 mark shed / secreted forms. This is a capability that a single-clone antibody cannot deliver, and one of the most compelling long-term applications of the Superpooled design.

Roadmap for IHC and IF validation

TPB is actively adding IHC and IF validation data across the catalogue. Priority targets are the highest-cited Superpooled families: BACE1/BACE2 (Alzheimer's research), MMP family (cancer / cardiovascular), cathepsins (neurodegeneration), and ADAM family (inflammation). When your target of interest has validation data, it will be published on the individual product pages and the corresponding datasheet PDF will include the recommended tissue prep, retrieval, and dilution starting points.

If you are running an active IHC or IF programme and your target is on the TPB catalogue, we're interested in your data — contact us via the SPA early-adopter enquiry and we can supply the pool at a reduced price for collaborative validation studies. Data generated in this way, once cited in the resulting publication, qualifies for the citation rebate programme.

How Triple Point designs an SPA pool

The design process for a Superpooled kit is:

  1. Domain map the target. Identify the propeptide, catalytic domain(s), any regulatory / adapter domains, and the C-terminal / cytoplasmic tail (if membrane-anchored). Reference UniProt, the crystal structure if available, and published cleavage-site data.
  2. Select immunogen peptides. One peptide per domain, chosen for (a) high antigenicity by hydrophilicity and secondary-structure prediction, (b) low sequence identity with the closest paralogues, (c) no known PTM sites within or immediately flanking the peptide. Typical peptide length is 15-20 residues.
  3. Raise independent polyclonals. Each peptide is coupled to KLH and used to immunise a separate rabbit cohort. Each polyclonal is affinity-purified against its own peptide.
  4. Characterise each polyclonal individually. Titre, epitope specificity, cross-reactivity against the closest paralogues, expected Western blot band size on positive control lysate. Each polyclonal ships with its own individual CoA.
  5. Determine the pooling ratio. By running each antibody on the same standard positive-control lysate and matching signal intensities, the pooling ratio is set so no single antibody dominates. Typical ratios range from 1:1:1 for balanced kits to 2:1:1 for kits where the catalytic-domain antibody drives sensitivity.
  6. Validate the pool. The pooled reagent is tested on the same lysate + a negative-control lysate + a paralogue panel to confirm the band pattern matches the expected multi-epitope map.

The kit ships with the individual polyclonals (each fully characterised) plus a kit-level CoA that specifies the recommended pooling ratio and expected band pattern. This gives the customer flexibility — use the pool for standard multi-epitope detection, use one antibody for a targeted question, or use each individually on separate lanes for full epitope-by-epitope resolution.

Catalogue structure — what an SPA kit contains

A typical three-antibody Superpooled kit for a membrane-anchored proteinase contains:

RP1 — propeptide

The number 1 in the SKU denotes the propeptide-directed polyclonal. Detects only the latent zymogen. Loss of RP1 signal indicates propeptide cleavage and activation.

RP2 — catalytic domain

The number 2 denotes the catalytic-domain polyclonal. Detects both zymogen and mature enzyme. Highest-sensitivity total-target detection. Raised against a paralogue-divergent surface loop where possible.

RP3 — C-terminal / cytoplasmic tail

The number 3 denotes the C-terminal-directed polyclonal. For membrane-anchored proteinases, distinguishes intact membrane-form from ectodomain-shed soluble form. For secreted proteinases, targets the hemopexin domain (MMPs) or C-terminal regulatory region.

RP4-RP5 — additional domains (kit-specific)

Some targets have additional resolvable domains — for example, MMPs with fibronectin-repeat insertions in the catalytic domain, or ADAM proteins with cysteine-rich and EGF-like domains. Kits for these targets include additional domain antibodies as needed.

The naming convention is consistent across the catalogue: RP1[target], RP2[target], RP3[target]. So for BACE1, the kit is RP1BACE1, RP2BACE1, RP3BACE1. For MMP-9, the kit is RP1MMP9 and its companion domain antibodies. The three-antibody pool for each target is available as the individual polyclonals; you can order the pool by ordering the individual antibodies together.

Availability across the catalogue

The Superpooled design is available for the highest-priority proteinase targets across the catalogue. Specifically:

  • BACE1 and BACE2 (aspartic proteinases)
  • Most cathepsins (cysteine and aspartic)
  • Full MMP family (matrix metalloproteinases)
  • ADAM family (a disintegrin and metalloproteinase)
  • ADAMTS family (a disintegrin and metalloproteinase with thrombospondin motifs)
  • Kallikreins (serine proteinases)
  • TMPRSS family (transmembrane serine proteinases)
  • Calpains, granzymes, caspases (selected members)

Where a Superpooled kit is available, the product page lists it. Where only a single domain antibody is available (typically because the target is small enough that only one domain is a viable immunogen), the product page notes it.

Conjugates and formats

Each individual antibody in an SPA kit is available in three additional formats:

  • Unconjugated (default) — standard rabbit polyclonal
  • Biotin-conjugated (SKU suffix -BIOTIN) — for streptavidin-based detection
  • HRP-conjugated (SKU suffix -HRP) — for direct ECL detection without secondary antibody
  • 15UL trial size (SKU suffix -15UL) — small-volume format for initial validation

The Superpooled protocol is the same across all four formats — the pool concentration and pooling ratio are calibrated to the working format.

How SPA compares to competitor approaches

The pooled-polyclonal concept is not unique to Triple Point. What distinguishes the SPA method is:

  1. Each polyclonal in the pool is individually characterised with its own CoA, not a single kit-level CoA describing average behaviour.
  2. The pooling ratio is defined and documented, not a "roughly equal mixture" statement.
  3. The individual antibodies are available separately, so the customer can revert to single-antibody detection for targeted questions.
  4. The expected band pattern is documented per target, based on measured detection of recombinant protein and validated cell lysate.

The result is a reagent that behaves reproducibly and interpretably, not just "works well on average."

Related